CUE Stock Jumps Over 100% After Hours — What’s Driving The Rally?

• The $30 million net proceeds from the placement will allow the company to advance its clinical pipeline, Cue said.
• Cue also announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases.
• The company named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.

Shares of Cue Biopharma (CUE) jumped nearly 100% after-hours on Thursday after the clinical-stage biotech company announced changes collectively aimed at strengthening its cash position, expanding its clinical pipeline, and bringing in new leadership.

The company announced a $30 million private placement, licensed a new clinical-stage drug candidate, and appointed a new CEO.

$30 Million Private Placement Bolsters Balance Sheet

Cue Biopharma entered into a securities purchase agreement with certain accredited investors for a private placement expected to raise gross proceeds of approximately $30 million before fees and expenses.

The company stated it will use the net proceeds to advance its clinical pipeline, support working capital, and fund general corporate purposes. The transaction is expected to close on or about May 4, 2026, subject to customary closing conditions.

Exclusive License Adds To Pipeline

Cue Biopharma further announced it has obtained an exclusive license from Ascendant Health Sciences for Ascendant-221, an experimental drug designed to treat certain allergic diseases. The license covers all territories except mainland China, Hong Kong, Macau, and Taiwan.

Cue plans to advance the asset into further studies, with near-term clinical data expected from an ongoing mid-stage trial in chronic spontaneous urticaria during the second half of 2026.

The company said that it will pay Ascendant $15 million upfront as a license fee, followed by up to an aggregate of $676.5 million in additional potential payments upon the achievement of certain milestones, in addition to tiered royalties on future sales of the drug.

Veteran Executive Shao-Lee Lin Named New CEO

Cue Biopharma also named Shao-Lee Lin as its new President, Chief Executive Officer, and member of the Board of Directors, effective immediately.

Lin previously founded and led the pharma company ACELYRIN, where she raised over $1 billion in capital and took the company public at a valuation exceeding $2 billion within three years. She has held senior roles at Horizon Therapeutics, AbbVie, Gilead Sciences, and Amgen.

How Did CUE Retail Traders React?

On Stocktwits, retail sentiment around CUE stock jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.

A Stocktwits user voiced optimism on the licensing deal.

Another use voiced hopes for the stock rallying as high as $50, implying a potential rally of about 100% from the stock’s last close.

A third user opined that the after-hours rally was a result of manipulation and a short squeeze.

CUE stock has fallen 35% over the past 12 months. 

Read More: Meta CEO Links Stock Drop To Higher Capex, Plans Team Cuts And More Apps: Report

For updates and corrections, email newsroom[at]stocktwits[dot]com.